These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27476490)

  • 1. Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.
    Clemow DB; Nyhuis AW; Robinson RL
    CNS Neurosci Ther; 2016 Dec; 22(12):970-978. PubMed ID: 27476490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
    Molife C; Haynes VS; Nyhuis A; Faries DE; Gelwicks S; Kelsey DK; Alatorre CI
    Curr Med Res Opin; 2018 Apr; 34(4):619-632. PubMed ID: 29298540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data.
    Van Brunt DL; Johnston JA; Ye W; Pohl GM; O'Hara NN
    J Manag Care Pharm; 2006 Apr; 12(3):230-8. PubMed ID: 16623607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity Disorder.
    Kabul S; Alatorre C; Montejano LB; Farr AM; Clemow DB
    CNS Neurosci Ther; 2015 Dec; 21(12):936-42. PubMed ID: 26331467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine monotherapy compared with combination therapy for the treatment of ADHD: a retrospective chart review study.
    Clemow DB; Mason OW; Sarkis EH; Ruff DD; Berman BD; Donnelly CL; Robb AS; Holland DS; Schuh KJ; Barnes JM; Araujo AB
    Expert Rev Neurother; 2015; 15(11):1353-66. PubMed ID: 26488905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
    Stuhec M; Locatelli I
    Int J Clin Pharm; 2018 Apr; 40(2):341-344. PubMed ID: 29468526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.
    Wietecha LA; Clemow DB; Buchanan AS; Young JL; Sarkis EH; Findling RL
    CNS Neurosci Ther; 2016 Jul; 22(7):546-57. PubMed ID: 26922462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
    Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA; Liebowitz M; Kronenberger W; Qiao M; Rubin R; Hollandbeck M; Deldar A; Schuh K; Durell T
    Depress Anxiety; 2009; 26(3):212-21. PubMed ID: 19194995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study.
    Surman C; Hammerness P; Petty C; Doyle R; Chu N; Gebhard N; Williams C; Biederman J
    CNS Neurosci Ther; 2010; 16(1):6-12. PubMed ID: 20070786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder.
    Waxmonsky JG; Waschbusch DA; Akinnusi O; Pelham WE
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):21-32. PubMed ID: 21288121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.
    Handen BL; Aman MG; Arnold LE; Hyman SL; Tumuluru RV; Lecavalier L; Corbett-Dick P; Pan X; Hollway JA; Buchan-Page KA; Silverman LB; Brown NV; Rice RR; Hellings J; Mruzek DW; McAuliffe-Bellin S; Hurt EA; Ryan MM; Levato L; Smith T
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):905-15. PubMed ID: 26506581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Lin HY; Gau SS
    Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.